New hope for ulcerative colitis patients who failed biologics?
Disease control
Not yet recruiting
This study tests an experimental drug called ATH-063 in 120 adults with moderate to severe ulcerative colitis who have not responded to or can no longer use biologic therapies. Participants will receive either the drug or a placebo for 12 weeks to see if it can reduce symptoms an…
Phase: PHASE2 • Sponsor: Athos Therapeutics Inc • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC